Physician profile
Suzanne Peck
NPI 1083811426
$51,429.51
in general payments reported to CMS, 2019-2025
32 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $12K · 2021: $5,127 · 2022: $4,463 · 2023: $1,978 · 2024: $1,487 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,650.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26,110.41 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Celgene Corporation | $5,166.22 | 2019 | |
| Leo Pharma INC. | $4,788.82 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $3,561.98 | 2019-2025 | Otezla, Otezla, Enbrel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $3,137.81 | 2019-2021 | |
| Abbvie INC. | $2,134.13 | 2019-2025 | |
| Janssen Biotech, INC. | $886.18 | 2019-2025 | Tremfya |
| Ucb, INC. | $723.10 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $531.13 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $516.43 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $512.75 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $472.90 | 2022-2024 | Vtama |
| Genzyme Corporation | $464.43 | 2021-2025 | |
| Pfizer INC. | $448.28 | 2019-2025 | |
| Incyte Corporation | $382.30 | 2022-2025 | Opzelura |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $324.52 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $250.41 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $207.57 | 2020-2025 | Nemluvio, Aklief |
| Vyne Pharmaceuticals INC. | $164.76 | 2021 | |
| Almirall LLC | $134.99 | 2019-2022 | |
| Mission Pharmacal Company | $77.41 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $72.44 | 2021 | |
| Mayne Pharma Commercial LLC | $67.21 | 2019 | |
| Ani Pharmaceuticals, INC. | $51.76 | 2025 | Purified Cortrophin Gel |
| Organon LLC | $45.16 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $42.84 | 2023 | Ycanth |
| Epi Health, LLC | $38.71 | 2020-2022 | |
| Prugen, INC. Pharmaceuticals | $37.75 | 2019 | |
| Journey Medical Corporation | $28.74 | 2022 | |
| Genentech USA, INC. | $17.74 | 2019 | |
| Medtronic Vascular, INC. | $15.36 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $15.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Peck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.